PDCD1 and melanoma: Interestingly, the incidence of any-grade fatigue was similar between adjuvant nivolumab and placebo (20% vs. 20%) and adjuvant pembrolizumab (an anti–PD-1 I-O therapy) and placebo (20% vs. 18%) in separate phase III trials (CheckMate 76K and KEYNOTE-716, respectively) involving patients with resected stage IIB or stage IIC melanoma [34,35].